<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806998</url>
  </required_header>
  <id_info>
    <org_study_id>Ketosterilrenal</org_study_id>
    <nct_id>NCT03806998</nct_id>
  </id_info>
  <brief_title>Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure</brief_title>
  <official_title>Effects of a Ketoacid Supplementation on Urinary Urea Nitrogen Excretion in Patients With Stage III to IV Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servicio de Salud Metropolitano Oriente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to demonstrate that a ketoacid supplement in patients with stage III
      to IV chronic renal failure, reduces the excretion of urinary urea nitrogen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with an estimated glomerular filtration rate of less than 25 ml/kg/min, not on renal
      substitution therapy, without important concomitant diseases and aged between 40 and 70
      years, will be invited to participate in the study. They will be randomly assigned to a group
      that will receive receive a supplement of ketoacids (Ketosteril) 1 tablet containing 630 mg
      of ketoacids every 5 kg of body weight and a diet containing 25 to 35 kcal/kg and 0.3
      g/protein per day or to a group receiving placebo and a diet containing 25 to 35 kcal/kg and
      0.6 g/protein per day. The intervention will last 16 weeks. At baseline and the end of the
      intervention a blood sample will be obtained to measure creatinine, urea nitrogen and
      cystatin C. Also a spot urine sample will be obtained to measure urea nitrogen and creatinine
      excretion. The compliance with the dietary prescription and the ketoacid or placebo
      supplement will be assessed every 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">October 1, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assgned to receive the ketoacid supplement or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>There will be no masking of the treatment arm for researchers</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated glomerular filtration rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>glomerular filtration rate estimated using the CKD-EPI formula for Cystatin-C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary urea nitrogen excretion</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measurement of urea nitrogen i na spot urine sample</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Ketoacid supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive a ketoacid supplement containing 630 mg of ketoacids in a dose of 1 tablet every 5 kg of body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive placebo tablets in a dose of 1 tablet every 5 kg of body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketoacids</intervention_name>
    <description>Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks</description>
    <arm_group_label>Ketoacid supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Provision of placebo capsules similar to active supplement</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimated glomerular filtration rate of less tan 25/ml/min/1.73m2

          -  Not on renal substitution therapy

          -  Absence of severe life threatening concomitant diseases

        Exclusion Criteria:

          -  Malignant or renovascular hypertension

          -  Use of systemic steroids or immunosuppressant drugs

          -  Alcohol or illicit drug abuse

          -  A body mass index of less tan 18 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Bunout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INTA University of Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital del Salvador</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chile</investigator_affiliation>
    <investigator_full_name>Eduardo Lorca</investigator_full_name>
    <investigator_title>Chief Cardiovascular Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 29, 2019</submitted>
    <returned>July 26, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

